Cardiol Therapeutics Inc (CRDL)

[Sirpeter]

Rock on...

[TrendTrade2016]

CRDL..ROCK SOLID WEEKLY TREND

[glenn1919]

CRDL...........................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783

[Sirpeter]

Still in it

[TrendTrade2016]

CRDL A BEAUTIFUL WEEKLY BREAK OUT!!!

[Singhania]

Analysts Think $CRDL is Undervalued

Last week, Canaccord Genuity lifted the PT to $8 from $6 on Cardiol Therapeutics Inc (NASDAQ: CRDL) – Potential gain of 260% from CMP.

Analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and with a PT of $9.

Moreover, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial.

$RSLS $MRNA $NVAX $INSM $KTRA $VTYX $SCPX

[Singhania]

$CRDL - Analysts Reaffirm Significant Upside Potential for Cardiol Therapeutics

Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) - The company is currently developing CardiolRx™ and CRD-38 therapies for heart diseases, including recurrent pericarditis, acute myocarditis, and heart failure.

The stock has the potential for further upside considering the fact that Cardiol will release topline data for its Phase 2 MAvERIC-Pilot clinical trial evaluating the efficacy of CardiolRx™ for the treatment of recurrent pericarditis sometime in early June, which, if positive, has the potential to send the stock higher.

Several analysts have reiterated that the stock has the potential for significant upside, further reaffirming Cardiol’s growth prospects.

For instance, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial.

According to Gantoss, Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has many things going in its favor right now heading into a critical Phase 2 trial readout in recurrent pericarditis in June that he believes will lead to a positive outcome.

“Clearly, a $160 million market cap does not do Cardiol justice. With positive data in Q2, the path to market becomes a slam dunk, and the stock should surge to the upside in response,” says Gantoss.

In addition, analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and issued a $9 price target, which implies that Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a potential upside of about 300% from current levels.

Read full details here https://www.nasdaq.com/press-release/analysts-consensus-reaffirms-significant-upside-potential-for-cardiol-therapeutics

[Monksdream]

CRDL under $3

[Singhania]

Canaccord Genuity - PT Raised By 33% to $8 – Potential 260% rise

$CRDL – More reason to like the stock. Analyst at Canaccord Genuity lifted the PT to $8 from $6 – Potential gain of 260% from CMP

Big Catalyst - Cardiol is conducting an additional open-label Phase II MAvERIC-Pilot study for CardiolRx in recurrent pericarditis. The study is expected to report 8-week top-line data in Early June.

The report Further Says - We have incorporated a $75M equity raise in 3Q24 based on a positive outcome from the recurrent pericarditis Phase II trial. We extended the out-year of our model from a previous 2028 to 2035. We additionally have reduced the EU WAC pricing to 45% of U.S. pricing which is in-line with the current WAC pricing of epidiolex (comparator by mechanism, not indication).

[Singhania]

$CRDL looks like a perfect buy here. Higher highs and higher lows, continuous uptrend, strong uptrend, M&A buzz in the industry, multi-year breakout. I just bought some and am not planning to sell them, at least not before $4–5.

[Sirpeter]

Just got some 2.18s

[Monksdream]

Russell 2000 ETF 12 months

[Sirpeter]

Small caps are getting hammered

[Monksdream]

CRDL under $2

[Monksdream]

CRDL 10Q due 3/26
Next day settlement 5/28 per SEC mandate

[TrendTrade2016]

CRDL...MONSTER BREAK OUT!

[Sirpeter]

Taking names and kicking ass...

[TrendTrade2016]

CRDL..HERES 2 BUCKS...MASTER CALLS THE BIGGEST PLAYS ON THE INTERNET.!!

[Sirpeter]

Next push.. ready to go

[TrendTrade2016]

CRDL...READY TO BREAK 2 BUCKS...WHAT A CALL....

[TrendTrade2016]

CRDL monster move here, another magical trend call!

[Monksdream]

I think Investors Hub has resolved the hack

[Sirpeter]

Monster play ahead...

[Monksdream]

CRDL new 52 week high

[Sirpeter]

Good call boss...moving up

[TrendTrade2016]

CRDL////BREAK OUT

[glenn1919]

CRDL...............................................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783

[Sirpeter]

Added

[TrendTrade2016]

CRDL....BLASTING UP

[TrendTrade2016]

CRDL...CLEAN 1.62 BREAK OUT!!!

[TrendTrade2016]

CRDL...BREAK OUT ON THE WEEKLY....VERY NICE

[subslover]

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Newsfile Corp.
Newsfile Corp
Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study

This is a Designated News Release.

Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") for the Company's lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis.

"The FDA's decision was based on pre-clinical data combined with initial clinical data from the Company's MAvERIC-Pilot Phase II study," commented Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development. "This designation reinforces the potential of CardiolRx™ to improve the lives of patients suffering with recurrent pericarditis, a debilitating heart disease associated with symptoms that adversely affect quality of life and physical activity."

The FDA grants ODD to a drug or biological product to prevent, diagnose, or treat a rare disease or conditions that affect fewer than 200,000 people in the United States. ODD provides benefits to sponsors including potential seven-year marketing exclusivity, exemptions from certain FDA fees, and tax credits for qualified clinical trials. Products with ODD may also qualify for accelerated regulatory review via Fast Track, Breakthrough Therapy, or Priority Review designations.

MAvERIC-Pilot (NCT05494788) is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis. In addition to standard safety assessments, MAvERIC-Pilot is designed to evaluate improvement in objective measures of this rare disease. The primary efficacy endpoint is the change, from baseline to eight weeks, in patient-reported pericarditis pain using an 11-point numeric rating scale ("NRS"). The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis. Secondary endpoints include the NRS score after 26 weeks of treatment, and changes in circulating levels of C-reactive protein, a commonly used clinical marker of inflammation. Importantly, the study will assess freedom from pericarditis recurrence.

Recurrent pericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart) that follows an initial episode (frequently resulting from a viral infection). Patients may have multiple recurrences. Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Significant accumulation of pericardial fluid and scarring can progress to life-threatening constriction of the heart. The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention. On an annual basis, the number of patients in the United States having experienced at least one recurrence is estimated at 38,000. Approximately 60% of patients with multiple recurrences (>1) still suffer for longer than 2 years, and one third are still impacted at 5 years. Hospitalization due to recurrent pericarditis is often associated with a 6-8-day length of stay and cost per stay is estimated to range between $20,000 and $30,000 in the United States.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the FDA to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent pericarditis (the MAvERIC-Pilot study; NCT05494788), an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fati

[Billy75]

Wife just saw this company today in Sarasota area for luncheon. What is the deal with them? They are going NASDAQ so I’m assuming they have to get this to $5 a share, right?

[12yearplan]

Market seems to have liked the update today:
https://stockhouse.com/news/press-releases/2023/03/29/cardiol-therapeutics-announces-year-end-2022-update-on-operations

[12yearplan]

[12yearplan]

Filings says it all - lean and mean:
https://www.sec.gov/Archives/edgar/data/1702123/000110465922117212/tm2227599d1_ex99-1.htm
https://quantisnow.com/insight/3668667
$CRDL

[12yearplan]

Yes, screamin' buy at historical lows..

[Porterhouse10]

Share price says it all $CRDL

[12yearplan]

Don't know Porter. Looks like the market is likin' the news today and why not I suppose - drugs seem to be workin':

https://stockhouse.com/news/press-releases/2022/11/07/cardiol-therapeutics-announces-study-results-demonstrating-protective-effects-of#BBSL20221107

[Porterhouse10]

Where's Steve Grasso now? Lmao

[Porterhouse10]

Grasso's I'm an Advisor to $CRDL pumps are working, people shorting his picks now

[12yearplan]

Don't lose at this price point historically; always time I suppose ;)
CRDL$
.. takin' away the freedom..

[Porterhouse10]

Trading sideways a bit here, not a bad sign

[12yearplan]

Two low ebbs/double bottom - must be a time of interest.

[Porterhouse10]

Steve Grasso must be so proud!

[12yearplan]

Haven't been following lately but chart looks at low ebb and..


Cardiol Omicron
As Omicron spreads like wildfire and hospitalizations increase, it is highly likely Cardiol Rx will be fast tracked. Retail investors have short memories but this is going to be huge: "High-risk patients with Cardiovascular Disease (CVD), hospitalized with COVID-19 CardiolRx Cardiol has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application to conduct a Phase II/III clinical trial investigating the efficacy and safety of CardiolRx in the treatment of hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease".

[Porterhouse10]

Looks like another Steve Grasso disappointment, chalk up another

[srloan]

Boom time coming soon !!!

[Porterhouse10]

Steve Grasso

[Renee]

CRTPF changed to CRDL. Moved to the Nasdaq from the OTC:


https://www.sec.gov/Archives/edgar/data/1702123/000106299321007173/form6k.htm


https://otce.finra.org/otce/dailyList?viewType=Deletions